Literature DB >> 33597272

Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining.

Qin Zhou1, Michelle E Howard1, Xinyi Tu1, Qian Zhu2, Janet M Denbeigh1, Nicholas B Remmes1, Michael G Herman1, Chris J Beltran1, Jian Yuan2,3, Patricia T Greipp4, Judy C Boughey5, Liewei Wang3, Neil Johnson6, Matthew P Goetz7, Jann N Sarkaria1, Zhenkun Lou8,3, Robert W Mutter9.   

Abstract

Proton Bragg peak irradiation has a higher ionizing density than conventional photon irradiation or the entrance of the proton beam profile. Whether targeting the DNA damage response (DDR) could enhance vulnerability to the distinct pattern of damage induced by proton Bragg peak irradiation is currently unknown. Here, we performed genetic or pharmacologic manipulation of key DDR elements and evaluated DNA damage signaling, DNA repair, and tumor control in cell lines and xenografts treated with the same physical dose across a radiotherapy linear energy transfer spectrum. Radiotherapy consisted of 6 MV photons and the entrance beam or Bragg peak of a 76.8 MeV spot scanning proton beam. More complex DNA double-strand breaks (DSB) induced by Bragg peak proton irradiation preferentially underwent resection and engaged homologous recombination (HR) machinery. Unexpectedly, the ataxia-telangiectasia mutated (ATM) inhibitor, AZD0156, but not an inhibitor of ATM and Rad3-related, rendered cells hypersensitive to more densely ionizing proton Bragg peak irradiation. ATM inhibition blocked resection and shunted more DSBs to processing by toxic ligation through nonhomologous end-joining, whereas loss of DNA ligation via XRCC4 or Lig4 knockdown rescued resection and abolished the enhanced Bragg peak cell killing. Proton Bragg peak monotherapy selectively sensitized cell lines and tumor xenografts with inherent HR defects, and the repair defect induced by ATM inhibitor coadministration showed enhanced efficacy in HR-proficient models. In summary, inherent defects in HR or administration of an ATM inhibitor in HR-proficient tumors selectively enhances the relative biological effectiveness of proton Bragg peak irradiation. SIGNIFICANCE: Coadministration of an ATM inhibitor rewires DNA repair machinery to render cancer cells uniquely hypersensitive to DNA damage induced by the proton Bragg peak, which is characterized by higher density ionization.See related commentary by Nickoloff, p. 3156. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33597272      PMCID: PMC8260463          DOI: 10.1158/0008-5472.CAN-20-2960

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

1.  Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation.

Authors:  Qi Liu; Priyanjali Ghosh; Nicole Magpayo; Mauro Testa; Shikui Tang; Liliana Gheorghiu; Peter Biggs; Harald Paganetti; Jason A Efstathiou; Hsiao-Ming Lu; Kathryn D Held; Henning Willers
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

2.  Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay.

Authors:  Yulia V Surovtseva; Vikram Jairam; Ahmed F Salem; Ranjini K Sundaram; Ranjit S Bindra; Seth B Herzon
Journal:  J Am Chem Soc       Date:  2016-03-09       Impact factor: 15.419

3.  Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.

Authors:  Dan L Longo
Journal:  N Engl J Med       Date:  2019-12-19       Impact factor: 91.245

4.  Exponential Increase in Relative Biological Effectiveness Along Distal Edge of a Proton Bragg Peak as Measured by Deoxyribonucleic Acid Double-Strand Breaks.

Authors:  John J Cuaron; Chang Chang; Michael Lovelock; Daniel S Higginson; Dennis Mah; Oren Cahlon; Simon Powell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-13       Impact factor: 7.038

5.  DNA end resection is needed for the repair of complex lesions in G1-phase human cells.

Authors:  Nicole B Averbeck; Oliver Ringel; Maren Herrlitz; Burkhard Jakob; Marco Durante; Gisela Taucher-Scholz
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Deficiency in homologous recombination renders Mammalian cells more sensitive to proton versus photon irradiation.

Authors:  Nicole Grosse; Andrea O Fontana; Eugen B Hug; Antony Lomax; Adolf Coray; Marc Augsburger; Harald Paganetti; Alessandro A Sartori; Martin Pruschy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-13       Impact factor: 7.038

7.  ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining.

Authors:  Hongyan Wang; Huichen Wang; Simon N Powell; George Iliakis; Ya Wang
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

8.  Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery.

Authors:  Anar K Murphy; Michael Fitzgerald; Teresa Ro; Jee Hyun Kim; Ariana I Rabinowitsch; Dipanjan Chowdhury; Carl L Schildkraut; James A Borowiec
Journal:  J Cell Biol       Date:  2014-08-11       Impact factor: 10.539

9.  Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.

Authors:  Matthew P Goetz; Krishna R Kalari; Vera J Suman; Ann M Moyer; Jia Yu; Daniel W Visscher; Travis J Dockter; Peter T Vedell; Jason P Sinnwell; Xiaojia Tang; Kevin J Thompson; Sarah A McLaughlin; Alvaro Moreno-Aspitia; John A Copland; Donald W Northfelt; Richard J Gray; Katie Hunt; Amy Conners; Hugues Sicotte; Jeanette E Eckel-Passow; Jean-Pierre Kocher; James N Ingle; Marissa S Ellingson; Michelle McDonough; Eric D Wieben; Richard Weinshilboum; Liewei Wang; Judy C Boughey
Journal:  J Natl Cancer Inst       Date:  2017-07-01       Impact factor: 13.506

10.  Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.

Authors:  Jia Yu; Bo Qin; Ann M Moyer; Jason P Sinnwell; Kevin J Thompson; John A Copland; Laura A Marlow; James L Miller; Ping Yin; Bowen Gao; Katherine Minter-Dykhouse; Xiaojia Tang; Sarah A McLaughlin; Alvaro Moreno-Aspitia; Anthony Schweitzer; Yan Lu; Jason Hubbard; Donald W Northfelt; Richard J Gray; Katie Hunt; Amy L Conners; Vera J Suman; Krishna R Kalari; James N Ingle; Zhenkun Lou; Daniel W Visscher; Richard Weinshilboum; Judy C Boughey; Matthew P Goetz; Liewei Wang
Journal:  Breast Cancer Res       Date:  2017-12-06       Impact factor: 6.466

View more
  2 in total

1.  Critical DNA damaging pathways in tumorigenesis.

Authors:  Jake A Kloeber; Zhenkun Lou
Journal:  Semin Cancer Biol       Date:  2021-04-24       Impact factor: 15.707

Review 2.  Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee.

Authors:  Robert W Mutter; J Isabelle Choi; Rachel B Jimenez; Youlia M Kirova; Marcio Fagundes; Bruce G Haffty; Richard A Amos; Julie A Bradley; Peter Y Chen; Xuanfeng Ding; Antoinette M Carr; Leslie M Taylor; Mark Pankuch; Raymond B Mailhot Vega; Alice Y Ho; Petra Witt Nyström; Lisa A McGee; James J Urbanic; Oren Cahlon; John H Maduro; Shannon M MacDonald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-05-25       Impact factor: 8.013

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.